Correlations between initial serum soluble interleukin 2 receptor (sIL-2R) values and parameters ofdisease activity.
Correlation coefficients calculated by Spearman rank analysis using the sIL-2R values during treatment and disease activity assessments higher in synovial fluid from patients with RA than in serum samples, indicating that serum levels may reflect the degree ofimmune activation within affected joints.8 9 We have confirmed previous findings that levels are increased in patients with RA.8 9 The levels showed no association with clinical parameters of disease activity, however. Previous studies have provided conflicting data in this respect; Wood et al reported moderate to good correlations in 13 patients with clinical indices similar to those used in our study,10 whereas Keystone et al, in a cohort of 77 patients, found no associations using a composite clinical index of disease activity supporting our observation. 9 The discrepancy between the articular index and sIL-2R levels may be due to lymphocyte infiltration of clinically unaffected joints. " A better association might have been observed if disease activity had been scored by more sensitive indicators of articular disease such as radionuclide joint scanning. 12 The moderate correlation with functional ability noted in this study needs to be further evaluated in a larger patient cohort, particularly as the association remained significant in a multivariate regression analysis (data not shown).
Some association was also observed between sIL-2R and C reactive protein and ESR, suggesting that sIL-2R is another acute phase reactant; this, however, is considered unlikely. Firstly, its biology does not suggest such a role; secondly, in this study levels did not change in the same direction as other acute phase reactants after treatment; and thirdly, levels are increased in conditions associated with a blunted acute phase response such as scleroderma. 3 Clinical improvement with second line drugs in patients with RA has been noted to be associated with a significant reduction in the intensity of the T cell infiltrate. 13 We, however, did not observe a change in lymphocyte activation as assessed by serum sIL-2R levels, though the clinical improvements with all three drugs were modest. These observations are not necessarily disparate as the effect on the number of T cells may be due to an effect of the drugs studied on endothelial cell proliferation with a concomitant reduction in the number of blood vessels and hence on the continuing recruitment of new lymphocytes, rather than on activation. '4 Alternatively, disease suppression may have not been sufficient to influence lymphocyte activation.
In conclusion, the results of this study suggest that sIL-2R probably measures 
